AMPH - CIK 0001297184
The table below shows Amphastar Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $170.18M | $151.61M | $144.30M | $156.10M | $126.35M | $92.64M |
| Short-term investments | $112.64M | $70.04M | $112.51M | $19.66M | $10.32M | $12.98M |
| Receivables | $143.56M | $136.29M | $114.94M | $88.80M | $78.80M | $66.00M |
| Inventory | $176.89M | $153.74M | $105.83M | $103.58M | $92.81M | $96.83M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $636.02M |
| $534.07M |
| $489.60M |
| $378.32M |
| $318.12M |
| $279.68M |
| Property, plant & equipment | $310.57M | $297.35M | $282.75M | $238.27M | $244.24M | $260.06M |
| Goodwill | $3.40M | $3.05M | $3.22M | $3.13M | $3.31M | $3.94M |
| Total assets | $1.63B | $1.58B | $1.51B | $741.99M | $671.53M | $631.24M |
| Accounts payable | $32.59M | $30.51M | $25.44M | $20.50M | $22.21M | $24.36M |
| Total current liabilities | $158.16M | $173.76M | $225.41M | $94.86M | $103.81M | $112.20M |
| Long-term debt | $619.71M | $613.53M | $603.17M | $76.64M | $78.19M | $45.92M |
| Total liabilities | $840.49M | $845.17M | $873.49M | $213.33M | $226.01M | $182.51M |
| Retained earnings | $666.88M | $568.79M | $409.27M | $271.72M | $180.34M | $117.77M |
| Total equity | - | - | - | - | $445.52M | $402.31M |